Innate Pharma Reported Q1 Revenue Of €6.6M Down From €26M YoY; Cash Position Of €113.9M
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024
- Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers
- Five ASCO Annual Meeting 2024 abstracts:
- Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides
- Two posters on IPH6501, Innate's second generation ANKET® in B‑cell Non-Hodgkin's Lymphoma
- AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial
- Monalizumab SCLC Phase 2 MOZART trial poster
- Cash position of €113.9 million1 as of March 31, 2024 (not including the €4.0 million payment to be received from Sanofi), anticipated cash runway into end 2025